Skip to main content

Change in Preferred Drug List Status for the Smoking Cessation Drug Class Effective May 16, 2023

Last updated on

Effective May 16, 2023, the Texas Health and Human Services Commission (HHSC) removed the non-preferred status from the generic product varenicline on the preferred drug list (PDL).

This removal occurred because of a drug shortage of the brand-name product Chantix in the smoking cessation drug class. The shortage is due to a manufacturing delay by the manufacturer, Pfizer.

To allow for any remaining stock to be used, the preferred status of Chantix products (NDC 00069-0468-56, 00069-0471-03, and 00069-0469-56) will not change.

As a result of the change, HHSC has removed the non-preferred status of the following generic drugs effective May 16, 2023:

National Drug Code

Generic Drug Name

49884015576

Varenicline 0.5 mg tablet

49884015676

Varenicline 1 mg tablet

49884094499

Varenicline starting month box

These changes will be reflected in the daily formulary file for managed care organizations (MCOs). The changes will allow providers to prescribe varenicline without a PDL prior authorization, and they will be able to continue providing the necessary medication to clients.

Email vdp-formulary@hhsc.state.tx.us with comments or questions.